This is Even More Dangerous | GLP-1s Go Underground S3E53

This conversation was inspired by a recent video of a teenaged US “diet coach” suggesting illegal use, as well as dosage, of retatrutide, while offering a means to acquire it on the gray market. Retatrutide is currently illegal to acquire in the US and Canada. Its expected release, upon approval by the FDA in the US, is late 2027 or early 2028.

Retatrutide is a “stacked” GLP-1, meaning it activates three hormone receptors. These are:

* GLP-1 (Glucagon-like peptide-1): Lowers blood sugar, slows stomach emptying, and signals fullness to the brain.

* GIP (Glucose-dependent insulinotropic polypeptide): Stimulates insulin release and works with GLP-1 to improve metabolic function.

* Glucagon (GCG): Stimulates energy expenditure and helps the body break down stored fat and liver fat.

Retatrutide has been observed to reduce weight by as much as 28% within a 52-week period, the speed of which can only assume muscle and bone loss.

Coach Tony Stewart has been helping clients who have unsuccessfully taken, or come off of, single-activator (agonist) GLP-1s.

Tony walks us through the many hurdles GLP-1s present, and explains the potentially negative impact of retatrutide, which is still being studied. Retatrutide is a bundle of “unknowns,” especially when taken without medical supervision, a nutrition education program, or exercise for muscle preservation, and worst of all, when purchased on the gray market, where the ingredients are unknown.

Notes from Tony on info given in the video:

* Longest randomized semaglutide trial: ~4 years

* Participants: 17,604

* Stopped because of side effects:

* Semaglutide: 16.6%

* Placebo: 8.2%

* Main reason for stopping: Gastrointestinal side effects (especially nausea and diarrhea)

* Total deaths:

* Semaglutide: 375 (4.3%)

* Placebo: 458 (5.2%)

Of those - 16% had Serious adverse events of which 33.4% were Semaglutide and 36.4% were Placebo.

The semaglutide group experienced fewer serious adverse events overall, largely because they had fewer major cardiovascular events…the primary outcome the study was designed to assess.

Reports cited by Tony:

Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

https://pubmed.ncbi.nlm.nih.gov/39948761/

Clinical review - semaglutide (Wegovy) - NCBI bookshelf

https://www.ncbi.nlm.nih.gov/books/NBK601688/

CONNECT WITH COACH TONY STEWART

YouTube video podcast The Meat of the Matter @MOTM2025, and Tony Stewart @tony_foodforthought

On the web at:

Tony Stewart Coaching

Tonystewartcoaching.com and

Life After GLP-1s

https://lifeafterglp1s.com

CONNECT WITH CARNIVORE EVOLUTION:

-Mark Ennis, health and fitness coach

ennismark93@gmail.com, and on both Instagram and YouTube @fitnessbeyondtime01 and @carnivoreevolution2024

-Victoria Olson, health coach and author of ‘Troubleshooting Your Carnivore Diet’ on Amazon https://a.co/d/00WnRF0I , can be reached at carnivoreevolution2024@gmail.com

And on Facebook in the group: Carnivore Diet After Age 40.

Thank you for watching and listening. Please Like, Comment and Subscribe. We make no profit. Your input helps us get the word out about the Carnivore diet.

#CarnivoreDiet #WeightLoss #ZeroCarb #AnimalBasedDiet #diet #coach #coaching #glp1 #retatrutide #wegovy #ozempic #semaglutide #semiglutide